The cumulative adequacy and outcome of all tested tumor samples in the cohort for the treatment predictive biomarkers and PD-L1 of two of the cohort subgroups, NSCLC adenocarcinoma, respectively NSCLC NOS, are shown in Table 5. This evidence concerns the gene CD274 and neoplasm.